XI’AN, China, May 13, 2025 — BON Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a major supplier of bio-ingredient solutions for the natural health and personal care sectors, today announced the launch of its new sleep health product line. Developed using the unique “Glucoraphanin-Myrosinase” delivery system (patent-pending), the Company intends this product to significantly improve the bio-activity (the degree to which a substance is absorbed and used by the body) of glucoraphanin, a crucial bio-active component found in broccoli, and will be marketed under the Company’s own brand.
Broccoli, a superfood rich in nutrients, contains glucoraphanin, a key bio-active compound that the body converts into sulforaphane. Sulforaphane has been associated with several health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects. However, the enzymatic conversion of glucoraphanin into its active form, sulforaphane, is inefficient, making it difficult for the body to fully reap the health benefits of broccoli. This poses challenges for nutritional use and commercial application.
The Company believes its patent-pending “Glucoraphanin-Myrosinase” represents a cutting-edge biotechnological delivery system. By ensuring optimal enzymatic activation in the body, it achieves improved conversion efficiency of bio-active sulforaphane. This system is intended to address fundamental bio-availability issues. With its precision-driven design, ease of use, and consumer-friendly format, the Company believes this innovation has transformative potential by repositioning glucoraphanin-sulforaphane in the health and wellness market, allowing the Company to take advantage of potential revenue opportunities.
“BON’s new sleep health products are designed to surpass traditional formulations with better bio-availability, increased biological potency, and user-friendly application,” emphasized Mr. Yongwei Hu, Chairman and CEO of BON. “Our Glucoraphanin-Myrosinase delivery system seeks to combine scientific precision with commercial viability. It tackles critical unmet needs in sleep health and, we believe, is poised for swift market acceptance. We expect this new product line to drive market expansion, thereby boosting the Company’s business growth. Moreover, the widespread adoption of this product category is expected to significantly reshape the dynamics of the sleep health market.”
About Bon Natural Life Limited (“BON”)
BON is a Cayman Islands-based company operating in the natural health and personal care sectors. For further details, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release includes statements that may be considered “forward-looking statements.” All statements that are not statements of historical fact are “forward-looking statements.” These forward-looking statements are typically identified by terms such as “believes,” “expects,” or similar expressions, and involve both known and unknown risks and uncertainties. While the Company believes that the expectations expressed in these forward-looking statements are reasonable, they are based on assumptions, risks, and uncertainties, and there is no guarantee that these expectations will be accurate. You should not unduly rely on these forward-looking statements, which are relevant only as of the date of this press release. The Company’s actual results may differ considerably from those anticipated in these forward-looking statements due to various factors, including those discussed in the Company’s periodic reports filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or those acting on its behalf are explicitly qualified in their entirety by these factors. The Company undertakes no obligation to update these forward-looking statements, except as required by securities laws.
“`
